The Lauren classification highlights the role of epithelialto-mesenchymal transition in gastric carcinogenesis: An immunohistochemistry study of the STAT3 and adhesion molecules expression

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 1, 2015, Pages 77-83

  Susman, Sergiu ^a,b   Barnoud, Raphaelle ^c   Bibeau, Frederique ^d   Borini, Francesco ^e   Pocard, Marc ^a,f   Tomuleasa, Ciprian ^g,h   Sabourin, Jean Cristophe ^a,i  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c CROIX ROUSSE HOSPITAL   (France)

^d Department of Pathology Oncology Institute   (France)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f University of Paris   (France)

^g IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Adhesion molecule; EMT; Gastric cancer; Stat3

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CELL ADHESION MOLECULE; STAT3 PROTEIN; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GASTRIC MUCOSA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PHENOTYPE; PROTEIN EXPRESSION; SOMATIC MUTATION; STOMACH CARCINOMA; TUMOR VOLUME; WORLD HEALTH ORGANIZATION; YOUNG ADULT; ADENOCARCINOMA; AGED; CHEMISTRY; CLASSIFICATION; CLINICAL TRIAL; EUROPE; MULTICENTER STUDY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; STOMACH TUMOR; TISSUE MICROARRAY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALPHA CATENIN; BETA CATENIN; BIOMARKERS, TUMOR; CADHERINS; CELL ADHESION MOLECULES; EPITHELIAL-MESENCHYMAL TRANSITION; EUROPE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84924145441     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.sus     Document Type: Article

References (62)

1. Price P, Sikore K. Stomach. In: Treatment of Cancer, 4th edn. London: Arnold Press, 2002; 583-599.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30. doi:10.3322/caac.21166
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
4. Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54: 3845-3852.
5. Tamura G, Yin J, Wang S, et al. E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569-573. doi:10.1093/jnci/92.7.569
6. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405. doi:10.1038/32918
7. Lei IB, Tan K, Das K, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013; 145: 554-565. doi:10.1053/j.gastro.2013.05.010
8. Tye H, Kennedy CL, Najdovska M, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012; 22: 466-478. doi:10.1016/j.ccr.2012.08.010
9. Kim MJ, Nam HJ, Kim HP, et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 2013; 335: 145-152. doi:10.1016/j.canlet.2013.02.010
10. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009; 4: 283-293. doi:10.1016/j.ccr.2009.02.015
11. Darnell J. STATs and gene regulation. Science 1997; 277: 1630-1635. doi:10.1126/science.277.5332.1630
12. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662. doi:10.1038/nrm909
13. Kim DY, Cha ST, Ahn DH, et al. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol 2009; 24: 646-651. doi:10.1111/j.1440-1746.2008.05671.x
14. Bu X, Zhao C, Wang W, Zhang N. GRIM-19 inhibits the STAT3 signaling pathway and sensitizes gastric cancer cells to radiation. Gene 2013; 512: 198-205. doi:10.1016/j.gene.2012.10.057
15. Huang S, Chen M, Shen Y, et al. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 2012; 315: 198-205. doi:10.1016/j.canlet.2011.10.011
16. Gritsko T, Williams A, Turkson J, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12: 11-19. doi:10.1158/1078-0432.CCR-04-1752
17. Amin HM, McDonnell TJ, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G[1] cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004; 23: 5426-5434. doi:10.1038/sj.onc.1207703
18. Zhang F, Li C, Halfter H, Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 2003; 22: 894-905. doi:10.1038/sj.onc.1206158
19. Hogstrand C, Kille P, Ackland ML, Hiscox S, Taylor KM. A mechanism for epithelial-mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). Biochem J 2013; 455: 229-237. doi:10.1042/BJ20130483
20. Davis FM, Azimi I, Faville RA, et al. Induction of epithelialmesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene 2014; 33: 2307-2316. doi:10.1038/onc.2013.187
21. Balanis N, Wendt MK, Schiemann BJ, et al. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectindependent STAT3 signaling pathway. J Biol Chem 2013; 288: 17954-17967. doi:10.1074/jbc.M113.475277
22. Cho KH, Jeong KJ, Shin SC, Kang J, Park CG, Lee HY. STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion. Cancer Lett 2013; 336: 167-173. doi:10.1016/j.canlet.2013.04.024
23. Moustakas A, Heldin CH. Signaling networks guiding epithelialmesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007; 98: 1512-1520. doi:10.1111/j.1349-7006.2007.00550.x
24. Yamashita S, Miyagi C, Fukada T, Kagara N, Che YS, Hirano T. Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature 2004; 429: 298-302. doi:10.1038/nature02545
25. Huber MA, Kraut N, Beug H. Molecular requirements for epithelialmesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-558. doi:10.1016/j.ceb.2005.08.001
26. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer 2002; 2: 442-454. doi:10.1038/nrc822
27. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890. doi:10.1016/j.cell.2009.11.007
28. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428. doi:10.1038/nrc2131
29. Buehler D, Hardin H, Shan W, et al. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 2013; 26: 54-61. doi:10.1038/modpathol.2012.137
30. Hwang-Verslues WW, Chang PH, Jeng YM, et al. Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc Natl Acad Sci U S A 2013; 110: 12331-12336. doi:10.1073/pnas.1222684110
31. Lemma S, Karihtala P, Haapasaari KM, et al. Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology 2013; 62: 326-333. doi:10.1111/his.12000
32. Montserrat N, Mozos A, Llobet D, et al. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum Pathol 2012; 43: 632-643. doi:10.1016/j.humpath.2011.06.021
33. Kalluri R. EMT: when epithelial cells decide to become mesenchymallike cells. The Journal of clinical investigation. J Clin Invest 2009; 119: 1417-1419. doi:10.1172/JCI39675
34. Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004; 23: 4921-4929. doi:10.1038/sj.onc.1207606
35. Kanai M, Konda Y, Nakajima T, et al. Differentiation-inducing factor-1 [DIF-1] inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene 2003; 22: 548-554. doi:10.1038/sj.onc.1206109
36. Denson LA. Adding fuel to the fire: STAT3 priming of gastric tumorigenesis. Gastroenterology 2006; 131: 1342-1344. doi:10.1053/j.gastro.2006.08.049
37. Sekikawa A, Fukui H, Fujii S, et al. REG Ialpha protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. Carcinogenesis 2008; 29: 76-83. doi:10.1093/carcin/bgm250
38. Kim DY, Cha ST, Ahn DH, et al. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol 2009; 24: 646-651. doi:10.1111/j.1440-1746.2008.05671.x
39. You W, Tang Q, Zhang C, et al. IL-26 promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation. PLoS One 2013; 21: e63588. doi:10.1371/journal.pone.0063588
40. Xu W, Chen GS, Shao Y, et al. Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/ PI3K/Akt pathway in human gastric cancer cells. Cancer Lett 2013; 332: 11-18. doi:10.1016/j.canlet.2012.12.030
41. Wei Z, Jiang X, Qiao H, et al. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal 2013; 25: 931-938. doi:10.1016/j.cellsig.2013.01.011
42. Inagaki-Ohara K, Mayuzumi H, Kato S, et al. Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice. Oncogene 2014; 33: 74-84. doi:10.1038/onc.2012.540
43. Judd LM, Bredin K, Kalantzis A, Jenkins BJ, Ernst M, Giraud AS. STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology 2006; 131: 1073-1085. doi:10.1053/j.gastro.2006.07.018
44. Howlett M, Giraud AS, Lescesen H, et al. The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development. Gastroenterology 2009; 136: 967-977. doi:10.1053/j.gastro.2008.12.003
45. Xiong H, Du W, Wang JL, et al. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl) 2012; 90: 1037-1046. doi:10.1007/s00109-012-0869-0
46. Lee J, Kang WK, Park JO, et al. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 2009; 117: 598-606. doi:10.1111/j.1600-0463.2009.02512.x
47. Kim DY, Cha ST, Ahn DH, et al. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol 2009; 24: 646-651. doi:10.1111/j.1440-1746.2008.05671.x
48. Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K, Sekine I. Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol 2007; 30: 437-442. doi:10.3892/ijo.30.2.437
49. Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013; 12: 26. doi:10.1186/1476-4598-12-26
50. Hu QD, Chen W, Yan TL, et al. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett 2012; 325: 207-213. doi:10.1016/j.canlet.2012.07.003
51. Jung MJ, Rho JK, Kim YM, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 2013; 32: 209-221. doi:10.1038/onc.2012.37
52. Yue P, Zhang X, Paladino D, et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 2012; 31: 2309-2322. doi:10.1038/onc.2011.409
53. Putoczki TL, Thiem S, Loving A, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013; 24: 257-271. doi:10.1016/j.ccr.2013.06.017
54. Zhang LL, Zhang J, Shen L, Xu XM, Yu HG. Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo. Mol Med Rep 2013; 7: 1387-1390. doi:10.3892/mmr.2013.1400
55. Zhang Y, Wang Q. Sunitinib reverse multidrug resistance in gastric cancer cells by modulating Stat3 and inhibiting P-gp function. Cell Biochem Biophys 2013; 67: 575-581. doi:10.1007/s12013-013-9544-5
56. Bu X, Zhao C, Wang W, Zhang N. GRIM-19 inhibits the STAT3 signaling pathway and sensitizes gastric cancer cells to radiation. Gene 2013; 512: 198-205. doi:10.1016/j.gene.2012.10.057
57. Huang S, Chen M, Shen Y, et al. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 2012; 315: 198-205. doi:10.1016/j.canlet.2011.10.011
58. Kim HP, Han SW, Song SH, et al. Testican-1-mediated epithelialmesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene 2014; 33: 3334-3341. doi:10.1038/onc.2013.285
59. Qian P, Banerjee A, Wu ZS, et al. Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. Cancer Res 2012; 72: 6036-6050. doi:10.1158/0008-5472.CAN-12-1507
60. Hsu KW, Hsieh RH, Huang KH, et al. Activation of the Notch1/ STAT3/Twist signaling axis promotes gastric cancer progression. Carcinogenesis 2012; 33: 1459-1467. doi:10.1093/carcin/bgs165
61. Peyser ND, Grandis JR. Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther 2013; 6: 999-1010. doi:10.2147/OTT.S47903
62. Giraud AS, Menheniott TR, Judd LM. Targeting STAT3 in gastric cancer. Expert Opin Ther Targets 2012; 16: 889-901. doi:10.1517/14728222.2012.709238